NCT02630030View on ClinicalTrials.gov

Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 24, 2016

Primary Completion Date

July 1, 2018

Study Completion Date

September 3, 2020

Conditions
Glioblastoma
Interventions
DRUG

Ixazomib

Given PO

Trial Locations (1)

30322

Emory University/Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Emory University

OTHER

NCT02630030 - Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | Biotech Hunter | Biotech Hunter